<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00591331</url>
  </required_header>
  <id_info>
    <org_study_id>SPN-107-07</org_study_id>
    <secondary_id>HTR 07-128384-111</secondary_id>
    <nct_id>NCT00591331</nct_id>
  </id_info>
  <brief_title>Phototoxicity Potential of NatrOVA Creme Rinse - 1%</brief_title>
  <official_title>Phase 1 Evaluation of the Phototoxic Potential of NatrOVA Creme Rinse - 1% in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ParaPRO LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ParaPRO LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the primary irritation potential of NatrOVA Creme Rinse - 1% in
      humans, after exposure to UV radiation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety endpoint will be visual grading of UV irradiated test sites and assessments of adverse experiences</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Head Lice</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NatrOVA Creme Rinse - 1%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NatrOVA Creme Rinse Vehicle Only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Blank patch</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spinosad (the active ingredient in NatrOVA)</intervention_name>
    <description>This is a patch test in which the test material is applied to the patch and the patch applied to the skin.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subjects 18-65 years of age and in good health.

          2. Fitzpatrick skin type I, II or III

        Exclusion Criteria:

          1. History of severe reactions from exposure to sunlight

          2. Known allergies or sensitivities to adhesives in patches

          3. Inability to evaluate the skin in and around the test sites

          4. Diabetes requiring medication

          5. Clinical significant skin disease

          6. Asthma or other severe respiratory disease

          7. Known immunological disorders such as HIV, AIDS, lupus,rheumatoid arthritis

          8. History or current skin cancer

          9. Mastectomy for cancer involving removal of lymph nodes draining the test sites

         10. Epilepsy

         11. Pregnancy, lactation, or planned pregnancy during study period

         12. Chronic use of systemic antihistamine medication within 14 days of screening

         13. Use of anti-inflammatory drugs within 2 days of Screening Visit 1

         14. Currently receiving allergy injections

         15. Use of immunosuppressive drugs

         16. Topical drugs used at the test site within 7 days of Screening Visit 1

         17. Current participation in any clinical trial

         18. Participation in any patch test for irritation or sensitization or UV exposures within
             4 weeks of study start

         19. Use of any investigational drug therapy within 4 weeks of study start.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John V Murray, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hill Top Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hill Top Research</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.parapro.com</url>
    <description>sponsor web site</description>
  </link>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2007</study_first_submitted>
  <study_first_submitted_qc>January 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2008</study_first_posted>
  <last_update_submitted>May 16, 2008</last_update_submitted>
  <last_update_submitted_qc>May 16, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2008</last_update_posted>
  <responsible_party>
    <name_title>David C. Rowe</name_title>
    <organization>ParaPRO, LLC</organization>
  </responsible_party>
  <keyword>Head Lice</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

